[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"visual-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:visual-impairment":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,42,75,107,129,168,201,221,248,276,306,345,373,405,450,475,504,533,553,577,612,642,663],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100644298","assessment-of-caries-impacts-and-experiences-in-a-visually-impaired-versus-sighted-children-using-caries-qca-100644298",false,"NCT07665047","Assessment of Caries Impacts and Experiences in a Visually Impaired Versus Sighted Children Using CARIES-QC\u002FA","Assessment of Caries Impacts and Experiences in a Visually Impaired Versus Sighted Pediatric Population Using a Caries-Specific Quality-of-Life Questionnaire: A Comparative Cross-sectional Study","Inclusion Criteria:\n\n* Children's age ranges from 6 to 14 years.\n* Apparently healthy children\n* Parents' acceptance of their children's participation in the study.\n\nExclusion Criteria:\n\n* Children on long-term medication.\n* Parents who refuse to participate in the study","ALL","6 Years","14 Years",{"count":20,"type":21},140,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to to compare dental caries impacts and experience among visually impaired and sighted children. The main question it aims to answer is:\n\nAmong schoolchildren aged 6-14 years, does visual impairment compared to normal sight lead to poorer caries experiences and lower caries-related quality of life?",[25],"Visual Impairment",[27,28,29],"visually impaired","caries","quality of life","NOT_YET_RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2027-08",{"name":40,"class":41},"Cairo University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100504184","phase-3-intravitreal-faricimab-injections-or-fluocinolone-acetonide-019-mg-intravitreal-implants-vs-observation-for-prevention-of-va-loss-due-to-radiation-retinopathy-100504184","NCT05844982","Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy","A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy","AL","Key Inclusion Criteria\n\n* Primary uveal melanoma (excluding iris melanoma) receiving primary treatment with plaque brachytherapy\n* Absence of unrelated cause of visual loss\n* Baseline visual acuity ≥ 34 letters (20\u002F200 Snellen equivalent or better)\n* Posterior tumor margin \\>0 mm from the center of the macula (i.e., tumor is NOT under the geometric center of the fovea)\n* Posterior tumor margin \\>0 mm from the closest disc margin (i.e., tumor is not touching the edge of the optic disc)\n* Calculated total dose to center of the macula ≥30 Gy\n\nKey Exclusion Criteria\n\n* Opaque media\n* Inability to undergo fluorescein angiography\n* Less than 18 years of age\n* Prior vitrectomy\n* Intraocular pressure (IOP) ≥ 25 mmHg or history of steroid- induced IOP elevation that required treatment at baseline\n* IOP ≥ 25 mmHg at randomization or increase in IOP ≥ 8 mmHg from baseline to randomization (following steroid challenge","18 Years",{"count":52,"type":21},600,"INTERVENTIONAL",[55],"PHASE3","This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.",[58,25],"Radiation Retinopathy",[60,61,62,63],"Visual Acuity","Radiation retinopathy","Faricima","Fluocinolone Acetonide","RECRUITING","2026-06-12",{"date":67,"type":34},"2026-06-15",{"date":69,"type":34},"2023-11-21",{"date":71,"type":21},"2029-12-26",{"name":73,"class":41},"Jaeb Center for Health Research",24,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":50,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":53,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100454619","touching-the-world-with-a-cane-cognitive-and-neural-processes-100454619","NCT05199896","Touching the World With a Cane: Cognitive and Neural Processes","Touching the World With a (Blind) Cane: Cognitive and Neural Processes","TOOL_TOUCH","Inclusion Criteria:\n\n* Man or woman, aged 18 to 60 years old\n* Give an informed consent by signature\n* Be part of the national health security system (registered to the Securité Sociale)\n* do not confuse his right and his left\n\nSpecific of the non-sighted participants:\n\n* Loss of vision happened at birth or 3-to 5 years later minimum in life\n* Must have a visual acuity inferior or equal to 4\u002F10\n* Be with a close relation for read information letter and sign the consent form if needed\n\nExclusion Criteria:\n\n* A person presenting an history of neurological, psychiatric or linguistic problems cannot be admitted\n* Assumption of psychotropic drugs\n* Pregnancy or breast-feeding woman\n* A person under legal tutoring\n* A person under care in other medical structure for reasons different from those of this research\n* A person under administrative or judiciary contention\n* A person who is not eligible to a MRI-exam according to the following criteria cannot be admitted to the experiments including MR acquisitions :\n\n  * Have a neurological, cardiac (battery) or defibrillator pacemaker\n  * Have a cardiac prosthesis (valve, stent...) or vascular prosthesis\n  * Have intracranial clips or clamps\n  * Carry a bypass of the cerebrospinal fluid\n  * Having metallic splinters in the eyes\n  * Wear metal prostheses (teeth, knees)\n  * Wear an infusion pump or system\n  * Be claustrophobic or have respiratory problems\n  * Have metal tattoos close to the head\n  * Have permanent make-up",true,"60 Years",{"count":86,"type":21},300,[88],"NA","The use of tools is ubiquitous in our lives and allows us to expand the sensorimotor capacities of our body. Much research has been done on the subject in sighted people over the past decades. This work has mainly focused on the motor aspect of using the tool, neglecting the sensory aspect. However, any action involving a tool carries sensory information, for example in the use of the white cane by blind people. 26% (\\> 200,000) of blind people in France use a white cane to get around. By sweeping the cane on the ground, they use it as a sensorimotor extension of their body to extract information from the environment in order to locate a pedestrian crossing or possible obstacles. While it is well established that the tools increase the user's motor skills, we have only just begun to clarify how they also function as sensory extensions of the user's body and how this phenomenon is potentially dependent on constant use of the tool to compensate for a missing sense, as is the case with blind people using a cane. The aim of this study is to fill this important gap in our knowledge.",[25,91],"Healthy",[93,94,95,96],"Blind\u002FNon-sighted","Healthy subject","fMRI","EEG","2026-03-20",{"date":99,"type":34},"2026-03-24",{"date":101,"type":34},"2022-04-20",{"date":103,"type":21},"2028-10",{"name":105,"class":41},"Hospices Civils de Lyon",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":53,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":106},"100534621","hemianopsia-rehabilitation-after-stroke-or-brain-injury-100534621","NCT06241209","Hemianopsia Rehabilitation After Stroke or Brain Injury","Inclusion Criteria:\n\nAll patients 18 years of age or older with a homonymous hemianopsia or quadrantopsia, who can provide informed consent, and communicate in English.\n\nExclusion Criteria:\n\n* The flashing lights from thge automated perimeter and PowerPoint program can potentially trigger photic seizures. Therefore patients with light-induced seizures are excluded.",{"count":114,"type":21},40,[88],"In patients with hemianopsia following stroke or brain injury, we will determine if stimulating the visual field with images from a PowerPoint slide set can increase the visual field.",[118,119,25],"Hemianopsia","Visual Field Defect, Peripheral","2026-03-13",{"date":122,"type":34},"2026-03-16",{"date":124,"type":34},"2024-01-25",{"date":126,"type":21},"2028-12-15",{"name":128,"class":41},"University of Alberta",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":53,"phases":138,"briefSummary":139,"conditions":140,"keywords":147,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":106},"100445805","improving-visual-field-deficits-with-noninvasive-brain-stimulation-100445805","NCT05085210","Improving Visual Field Deficits With Noninvasive Brain Stimulation","Visual Restoration of Losses Caused by Cortical Damage: a New Protocol to Promote Fast Recovery","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Presence of some intact visual cortical areas (other than primary visual cortex) in the damaged brain hemisphere. This assessment will be made from MRI or CT scans of the subject's head, which will be obtained via standard release from their neurologist.\n3. First ever ischemic or hemorrhagic stroke with damage to primary visual cortex, and rendered blind over a portion of their visual field.\n\n   * Ischemic stroke patients will be either subacute (within 6 months of their stroke) or chronic (more than 6 months)\n   * Hemorrhagic stroke patients will be chronic only (greater than 6 months)\n4. Must demonstrate a clear deficit in either simple or complex visual perception in portions of their visual field as measured by visual perimetry.\n5. Imaging evidence that the stroke is primarily affecting the visual cortex.\n6. Willing and able to participate in the study protocol and to comply with study procedures.\n\nExclusion Criteria:\n\n1. No evidence of damage to the primary visual cortex.\n2. Visual cortex damage as a result of a subsequent stroke (not primary).\n3. Total cortical blindness, covering both left and right visual fields.\n4. Unable to fixate visual targets precisely or unable to perform the visual training exercises as directed.\n5. Complete loss of reading abilities.\n6. Current or prior history of any neurological disorder other than stroke, such as epilepsy, a progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions other than the qualifying stroke lesion.\n7. Current history of poorly controlled migraines including chronic medication for migraine prevention.\n8. History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or immediate (1st degree relative) family history of epilepsy; with the exception of a single seizure of benign etiology (e.g. febrile seizure) in the judgment of the investigator.\n9. History of fainting spells of unknown or undetermined etiology that might constitute seizures.\n10. Past or current history of major depression, bipolar disorder or psychotic disorders, or any other major psychiatric condition.\n11. Participants who are suffering from one-sided attentional neglect as determined by standard neuropsychological tests: figure cancellation and line bisection tasks.\n12. Contraindication for receiving tRNS.\n13. Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.).\n14. Any complex, uncontrolled\u002Funstable or terminal medical illness.\n15. Substance abuse or dependence within the past six months.\n16. Medications will be reviewed by the responsible MD (Drs. Sandeep Kumar or Dan Press) and a decision about inclusion will be made based on the following: The patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination of CNS active drugs.\n17. All female participants that are pre-menopausal will be required to have a pregnancy test; any participant who is pregnant or breastfeeding will not be enrolled in the study.\n18. Subjects who, in the investigator's opinion, might not be suitable for the study.\n19. A hair style or head dress that prevents electrode contact with the scalp or would interfere with the stimulation (for example: thick braids, hair weave, afro, wig).\n20. Additional criteria for Group 1b only: Contraindication for using VR technology, specifically an implanted medical device such as a pacemaker, implanted defibrillator, deep brain or vagal nerve stimulator. Participants with a history of seizures are already excluded per the above criteria.","80 Years",{"count":74,"type":21},[88],"This is a randomized, pilot interventional study in participants with visual field deficit (VFD) caused by cortical lesion. Damage to the primary visual cortex (V1) causes a contra-lesional, homonymous loss of conscious vision termed hemianopsia, the loss of one half of the visual field. The goal of this project is to elaborate and refine a rehabilitation protocol for VFD participants. It is hypothesized that visual restoration training using moving stimuli coupled with noninvasive current stimulation on the visual cortex will promote and speed up recovery of visual abilities within the blind field in VFD participants. Moreover, it is expected that visual recovery positively correlates with reduction of the blind field, as measured with traditional visual perimetry: the Humphrey visual field test or an eye-tracker based visual perimetry implemented in a virtual reality (VR) headset. Finally, although results will vary among participants depending on the extent and severity of the cortical lesion, it is expected that a bigger increase in neural response to moving stimuli in the blind visual field in cortical motion area, for those participants who will show the largest behavioral improvement after training. The overarching goals for the study are as follows: Group 1a will test the basic effects of transcranial random noise stimulation (tRNS) coupled with visual training in stroke cohorts, including (i) both chronic\u002Fsubacute ischemic and chronic hemorrhagic VFD stroke participants, and (ii) longitudinal testing up to 6 months post-treatment. Group 1b will test the effects of transcranial tRNS coupled with visual training on a Virtual Reality (VR) device in stroke cohorts, including both chronic\u002Fsubacute ischemic and chronic hemorrhagic VFD stroke participants. Group 2 will examine the effects of tRNS alone, without visual training, also including chronic and subacute VFD stroke participants and longitudinal testing.",[119,141,25,118,142,143,144,145,146],"Stroke","Quadrantanopia","Cortical Blindness","Visual Field Defect Homonymous Bilateral","Occipital Lobe Infarct","Visual Fields Hemianopsia",[148,149,150,151,152,153,154,155,156,157,158],"Visual Field defects","Occipital Stroke","Ischemic Stroke","visual cortex","noninvasive brain stimulation","transcranial direct current stimulation","visual training","visual recovery","vision loss","quadrantanopia","Hemorrhagic stroke","2026-03-03",{"date":161,"type":34},"2026-03-04",{"date":163,"type":34},"2022-01-25",{"date":165,"type":21},"2026-06",{"name":167,"class":41},"Beth Israel Deaconess Medical Center",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":178,"conditions":179,"keywords":187,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100562510","visual-frailty-in-ageing-100562510","NCT06604104","Visual Frailty in Ageing","Seeing Through Their Eyes - Towards Defining Visual Frailty in Ageing","VFiA","Inclusion Criteria:\n\n* Participants should be residents of Scotland aged 60 years and above with a known diagnosis of advanced AMD.\n* The patients should be receiving treatment from Princess Alexandra Eye Pavilion (PAEP) for at least 6 months and should be responding positively to the treatment. This is to rule out poor results due to either not receiving medication or non-compliance.\n* The participants should be able to provide informed consent before taking part in the study.\n\nExclusion Criteria:\n\n* Participants who cannot speak and read English language will not be included in this pilot study. However, non-English speakers will be included in the future together with interpreters at the validation phase of the developed tool.\n* Participants who have undergone invasive ocular surgery like cataract extraction in their previous visit.\n* The potential participants who fail to provide or do not provide informed consent will not be included in the study.",{"count":177,"type":21},20,"The goal of this observational study is to define visual frailty and refine monitoring for an ageing population. It involves piloting a visual frailty assessment tool in a cohort of patients aged 60 and above with a known diagnosis of Age-related Macular Degeneration (AMD) in Princess Alexandra Eye Pavilion (PAEP), Anne Rowling Clinic which is hosting the NHS Low Visual Aid Clinic, or any other NHS Lothian facility treating patients with Age-related Macular Degeneration (AMD). The main questions it aims to answer are:\n\n* What is visual frailty and how can it be assessed or predicted in the global ageing population using visual acuity, reading performance, functional status, mental health and systemic co-morbidities?\n* What is the relationship between visual acuity, reading performance, ocular diagnosis, co-morbidities, mental health, and functional status?\n\nParticipants will have the following data collected from them from either Princess Alexandra Eye Pavilion, Anne Rowling Clinic which is hosting the NHS Low Visual Aid Clinic, or any other NHS Lothian facility treating patients with Age-related Macular Degeneration (AMD):\n\n* Visual acuity (both distance and near)\n* Reading performance\n* Functional status\n* Mental health\n* Co-morbidities\n\nData will also be collected remotely (by phone call) from both the participants and their carers\u002Frelatives about their perceptions of visual frailty.\n\nExpert opinion will be sought from optometrists and ophthalmologists about the concept of visual frailty using an online survey.",[180,181,182,183,184,185,186,25],"Frailty","Age-Related Macular Degeneration","Functional Status","Mental Health","Depression","Anxiety","Cognitive Impairment",[188,180,189,190,191],"Visual frailty","Ageing","Reading performance","Age-related Macular Degeneration (AMD)","2026-03-02",{"date":161,"type":34},{"date":195,"type":34},"2025-04-09",{"date":197,"type":21},"2027-02",{"name":199,"class":41},"University of Edinburgh",2,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":83,"sex":16,"minAge":50,"maxAge":136,"enrollmentInfo":208,"targetDuration":4,"studyType":53,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":106},"100626963","virtual-assistance-for-daily-living-neurophysiological-and-functional-effects-in-low-vision-100626963","NCT07442461","Virtual Assistance for Daily Living: Neurophysiological and Functional Effects in Low Vision","Effects of Visual Impairment on Neurophysiological Responses and the Feasibility and Impact of Multimodal Virtual Assistance for Instrumental Activities of Daily Living in Low Vision Populations","Inclusion Criteria:\n\nPeople with Visual Impairment:\n\n* Age between 18 and 80 years.\n* Diagnosis of visual impairment (any level, any etiology).\n* Current use of a primary mobility assistive device (e.g., white cane or guide dog).\n* Ability to travel independently (without assistance from another person).\n* Capacity to provide informed consent.\n* Willingness to complete all study-related assessments and procedures\n\nHealthy Controls:\n\n* Age between 18 and 80 years.\n* No self-reported visual impairment or use of mobility assistive devices.\n* Capacity to provide informed consent.\n* Willingness to complete all study-related assessments and procedures.\n\nExclusion Criteria:\n\n* Significant cognitive dysfunction (score \\\u003C24 on Folsteins' Mini Mental Status Examination)\n* Previous neurological illness, complicated medical condition (inclusive of comorbid cognitive impairment)\n* Significant mobility restrictions; people using walkers and wheelchairs\n* Pregnancy\n* Profound auditory impairments (i.e., cannot understand human speech)\n* Somatosensory impairments to the trunk or torso that precludes use of the haptic interfaces\n* Significant depression (score \\> 11 on the Geriatric Depression scale)",{"count":209,"type":21},150,[88],"This study aims to investigate how visual impairment affects neurophysiological and biomechanical responses during real-world navigation and daily activities, with a focus on the rehabilitative feasibility and impact of assistive technologies. These technologies include applications and wearable devices designed to support various aspects of daily living for individuals with visual impairment. The VIS4ION platform (Visually Impaired Smart Service System for Spatial Intelligence \\& On-board Navigation), a wearable system providing tactile and auditory feedback, is one component of this broader study. VIS4ION is designed to enhance environmental awareness and reduce cognitive load during mobility tasks for the visually impaired.",[25],"2026-02-25",{"date":192,"type":34},{"date":216,"type":21},"2026-03-01",{"date":218,"type":21},"2028-12-30",{"name":220,"class":41},"NYU Langone Health",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":53,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":106},"100587914","michigan-screening-and-intervention-for-glaucoma-and-eye-health-through-telemedicine-sight-2-100587914","NCT06934577","Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2","Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine- SIGHT 2: A Pragmatic Randomized Trial","SIGHT","Inclusion Criteria:\n\n• Speak English, Spanish, Arabic, Chinese, French, Hindi, Finnish, Albanian, Russian or Tagalog\n\nExclusion Criteria:\n\n* significant eye pain\n* sudden decrease in vision within one week\n* binocular diplopia\n* cognitive impairment\n* pregnancy\n* previously declined participation",{"count":230,"type":21},900,[88],"To compare eye disease detection rates at a Federally Qualified Health Center between a technology-enhanced protocol and standard optometric clinical examination for three of the leading causes of blindness: glaucoma, diabetic retinopathy, and visually significant cataract.",[234,25,235],"Eye Diseases","Glaucoma",[237,238],"Eye disease screening","Glaucoma detection","2025-12-12",{"date":241,"type":34},"2025-12-15",{"date":243,"type":34},"2025-12-04",{"date":245,"type":21},"2030-08",{"name":247,"class":41},"University of Michigan",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":254,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":53,"phases":258,"briefSummary":259,"conditions":260,"keywords":264,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":106},"100441464","development-of-a-multi-sensory-rehabilitation-program-for-people-with-ultra-low-vision-100441464","NCT05028712","Development of a Multi-sensory Rehabilitation Program for People With Ultra Low Vision","Inclusion Criteria:\n\n* People with ultra low vision (visual acuity ≤20\u002F1600)\n\nExclusion Criteria:\n\n* \\\u003C12 years of age\n* dependent on sighted guide\n* cognitive impairment","12 Years","99 Years",{"count":257,"type":21},36,[88],"This research is aimed to address one of the big gaps in the current vision rehabilitation protocols for people with profound visual impairment by evaluating a multisensory approach. There are a growing number of clinical trials that recruit people with end-stage eye diseases and the rehabilitation plan following various treatments is not clear. It is important to address this in order to maximize the efficacy of such treatments and to improve the quality of life in people with profound visual impairment.",[261,25,262,263],"Low Vision Blindness","Quality of Life","Functional Visual Loss",[265,266,267],"ultra low vision rehabilitation","multi sensory","functional vision assessment",{"date":269,"type":34},"2025-12-11",{"date":271,"type":34},"2024-03-08",{"date":273,"type":21},"2026-07",{"name":275,"class":41},"State University of New York College of Optometry",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":53,"phases":285,"briefSummary":286,"conditions":287,"keywords":294,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":200},"100591776","evaluation-of-serum--and-oct-biomarkers-in-patients-with-dme-treated-with-anti-vegf-or-dexamethasone-implant-100591776","NCT06984822","Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant","Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant","BiomarkerOCT","Inclusion Criteria:\n\n* Type I or type II DM.\n* DME involving the center of the fovea with CFT more than 280 microns and the presence of intraretinal cysts.\n\nExclusion Criteria:\n\n* Prior history of any other macular disease.\n* Previous treatment with dexamethasone implants in the last six months for those in the anti-VEGF group.\n* Previous treatment with anti-VEGF in the last two months for those in the dexamethasone implant group.\n* Prior vitreoretinal surgery.\n* Previous laser treatment of the macula.\n* Previous panretinal photocoagulation.\n* Ocular surgery in the previous 3 months.",{"count":209,"type":21},[88],"This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).",[288,25,289,290,291,292,293],"Diabetic Macular Edema","Diabetes Mellitus","Hyperglycaemia (Diabetic)","Oxidative Stress","Vascular Endothelial Growth Factor","VEGF",[295],"optical coherence tomography","2025-11-17",{"date":298,"type":34},"2025-11-21",{"date":300,"type":34},"2025-08-01",{"date":302,"type":21},"2028-12-31",{"name":304,"class":305},"Vastra Gotaland Region","OTHER_GOV",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":53,"phases":314,"briefSummary":315,"conditions":316,"keywords":324,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":106},"100598594","developing-evidence-based-cognitive-approaches-to-improve-adjustment-to-vision-loss-100598594","NCT07073521","Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss","Inclusion Criteria:\n\n* Adults who are at least 18 years old\n* Experiencing varying degrees of vision loss (e.g. mild, moderate, severe)\n* Willingness to participate in the focus group or pilot testing and provide feedback\n\nExclusion Criteria:\n\n* Individuals with severe cognitive impairment affecting participation\n* Congenital blindness\n* Recent or current participation in another clinical trial study or medical intervention that may interfere with study results\n* Documented or self-reported health condition that may interfere with the outcomes of this study.\n* Deemed unfit to participate in the study by the site investigator\n* Unwilling and\u002For unable to participate or provide consent",{"count":313,"type":21},45,[88],"The goal of this study is to develop and pilot test a therapeutic strategy combining cognitive behavioral therapy (CBT) with mindfulness practices tailored for individuals adjusting to vision loss. The study will begin with focus groups to inform the design of the intervention. Participants will complete brief surveys on their background and experiences with vision loss prior to attending a focus group, and some may be invited to a second session to provide additional feedback before preliminary testing begins. In the pilot phase, participants will attend weekly group therapy sessions using the developed intervention and complete assessments before and after the program, including questions about vision status, demographics, and experiences with vision loss.",[317,25,318,319,320,321,322,323],"Depression, Anxiety","Adjustment","Adjustment Disorder With Anxious Mood","Adjustment Disorder With Depressed Mood","Blindness, Acquired","Blindness and Low Vision","Vision Loss",[325,326,327,328,329,330,331,332,333,334,335],"Visually impaired","Blind","Vision loss","mental health","CBT","Cognitive-behavioral therapy (CBT)","mindfulness","adjustment to vision loss","focus group","pilot test","group therapy","2025-07-25",{"date":338,"type":34},"2025-07-30",{"date":340,"type":34},"2025-07-14",{"date":342,"type":21},"2027-07-13",{"name":344,"class":41},"The Chicago Lighthouse",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":352,"maxAge":136,"enrollmentInfo":353,"targetDuration":4,"studyType":53,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":106},"100516157","glaucoma-rehabilitation-with-action-video-games-and-exercise---grade-100516157","NCT06000865","Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE","The GRADE Randomized Trial: Glaucoma Rehabilitation With Action viDeo Games and Exercise","Inclusion Criteria:\n\n1. Presence of moderate to severe bilateral glaucomatous optic neuropathy (GON) from primary open-angle (including normal tension) or angle-closure glaucoma, as determined by an ophthalmologist, with abnormal Glaucoma Hemifield Test on standard Humphrey Field Analyzer 24-2 testing and matching nerve-fiber layer thinning on optical coherence tomography;\n2. Stable vision and visual field loss for at least 3 months;\n3. With a best-corrected distance acuity of 6\u002F12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved);\n4. With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (to confirm participants' intact cognitive function).\n\nExclusion Criteria:\n\n1. Advanced glaucoma with GON of median deviation worse than -25 decibel;\n2. Ocular diseases other than glaucoma (e.g., age-related macular degeneration, diabetic retinopathy, and moderate to severe cataract);\n3. Severe medical problems (e.g., stroke, Parkinson's disease) or self-reported neurological (e.g. brain surgery, brain tumor and peripheral neuropathy), or cognitive disorders (e.g., diagnosed dementia or cognitive impairment);\n4. Physical impairments (e.g. need the use of orthopedic and mobility aids) or physical limitations restricting them from independent walking;\n5. Self-reported or medically diagnosed vestibular\u002F cerebellar dysfunction, history of vertigo, or severe hearing loss;\n6. Using any medications for any neurological conditions or psychiatric drugs (e.g. sedative, hypnotic) that might interfere motor control; and\n7. Currently attending any intensive physical\u002Fbalance training.","55 Years",{"count":354,"type":21},56,[88],"Falls are one of the most serious public health concerns for seniors, with significant medical and economic consequences. This concern is even higher in patients with peripheral field loss due to glaucoma because of the patients' compromised visual input. The investigators' project proposes an innovative, entertaining, easily accessible and enjoyable intervention for improving mobility and postural control function in glaucoma patients with peripheral vision loss, who are more prone to falls and suffer from fear of falling. The new intervention examined in this project can be implemented in current vision and balance rehabilitation programs, and may benefit patients with different types of visual impairment to minimize their risk of falls and improve their quality of life.",[235,25],[235,359,360,361,362,363],"Peripheral field loss","Action video games","Balance functions","Fear of falling","Quality of life","2025-07-24",{"date":366,"type":34},"2025-07-28",{"date":368,"type":34},"2023-09-09",{"date":370,"type":21},"2025-12-30",{"name":372,"class":41},"The Hong Kong Polytechnic University",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":380,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":53,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":106},"100595755","easy-to-read-content-effectiveness-evaluation-100595755","NCT07036575","Easy-to-Read Content Effectiveness Evaluation","Integrated Program for Promoting Visual Health and Technological Applications for Individuals With Intellectual Disabilities","Inclusion Criteria:\n\n* Children and adolescents aged 3 to under 18\n* Children and adolescents with intellectual disabilities and developmental delays.\n* Children and adolescents who are able to correctly identify at least two out of the three images in the pre-assessment phase.\n\nExclusion Criteria:\n\n* Severe cognitive impairments, hearing impairments, speech disorders, or motor disabilities that would interfere with assessment procedures or participation in the instructional activities.","3 Years","17 Years",{"count":383,"type":21},250,[88],"Individuals with intellectual disabilities face challenges in accessing medical services and health education due to communication barriers and limited support tools. Traditional information delivery methods often fail to meet their needs, leading to unequal access to preventive care and early screening.\n\nThis integrated program aims to promote visual health among individuals with intellectual disabilities through the development and implementation of inclusive technologies. The program consists of three sub-projects:\n\n1. Visual Health Promotion and Development of an Inclusive Information Platform for Individuals with Intellectual Disabilities - developing accessible health materials for individuals with intellectual disabilities and their families.\n2. Development and Promotion of a Digital Visual Health Screening System for Individuals with Intellectual Disabilities - designed to support early detection and intervention tailored to this population.\n3. Development of a Healthcare Access Platform and Assistive Technologies for Individuals with Intellectual Disabilities - reducing communication barriers during medical visits through technological support.\n\nPreviously, our team developed and tested easy-to-read (ETR) materials with adults with intellectual disabilities, focusing on medical visits, eye diseases, and eye care. Once validated, these materials are planned to be adapted into digital versions and serve as the foundation for an online platform.\n\nTo evaluate the effectiveness of ETR content, we will conduct an experimental study with 250 children and adolescents with special needs from across Taipei and New Taipei City in Taiwan. Participants will receive different types of visual health education, and outcomes will be measured by improvements in their knowledge. This study aims to validate the impact of ETR resources in reducing health information inequality and improving visual health awareness in this underserved population.",[387,388,25],"Health Knowledge","Intellectual Developmental Disorder",[390,391,392,393,394,395],"Easy-to-Read","intellectal disability","children","special needs","visual impairment","vision health education","2025-06-17",{"date":398,"type":34},"2025-06-25",{"date":400,"type":21},"2025-06",{"date":402,"type":21},"2026-12",{"name":404,"class":41},"National Taiwan University Hospital",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":415,"conditions":416,"keywords":430,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":4},"100590537","project-icope-brazil-assessment-of-intrinsic-capacity-in-brazilian-older-adults-100590537","NCT06968702","Project ICOPE Brazil: Assessment of Intrinsic Capacity in Brazilian Older Adults","Project ICOPE Brazil: Assessment of Intrinsic Capacity in Older Adults as a Basis for Implementation of the WHO ICOPE Strategy in the Unified Health System.","ICOPE-BR","Inclusion Criteria:\n\n* People aged ≥ 60 years, with no age limit;\n* Being registered (with available contact information) in the participating health care units;\n* Being available to go in person to the data collection sites for the assessments.\n\nExclusion criteria\n\n* Inability to access the data collection site;\n* Severe neurologic and\u002For cognitive impairments that preclude interaction with the evaluators to complete the proposed tests and data collections;\n* Advanced serious illness or under palliative care:\n\nClinical Frailty Scale (CFS)20 score of 8 (severely frail) or 9 (terminally ill).",{"count":414,"type":21},3838,"The ICOPE Brazil study aims to understand aging trajectories in Brazil, especially healthy aging trends based on intrinsic capacity, a collective of mental and physical capacities one may have to maintain their functional ability to execute daily life activities. Tests and questionnaires will be applied to collect data on mobility capacity, cognitive capacity, nutritional status, vision, and hearing (sensorial) capacities, and mental health. These assessments are in consonance with what the World Health Organization proposed in the Integrated Care for Older People Program (ICOPE). Participants will be followed up for three years, and the primary outcomes of interest are loss of intrinsic capacity, mobility impairment, cognitive impairment, incident depressive symptoms, loss of functional ability, incident frailty, incident sarcopenia, incident falls, hospitalization, multimorbidity, and mortality.",[417,180,418,419,420,421,422,186,423,424,60,25,425,426,427,428,429],"Intrinsic Capacity","Aging","Healthy Aging","Functional Ability","Mobility and Independence","Cognitive Ability, General","Sensory Hearing Loss","Sensory Deficits","Mood Disorders","Depressive Symptoms","Vitality","Nutritional Risk","Nutrition Assessment",[431,420,432,433,434,180,186,435,436,427,437,438,439,440],"Instrinsic Capacity","ICOPE","Aging trends","Older Adults","Mobility","Sensory","Psychological","Cohort","healthy aging","public health","2025-05-05",{"date":443,"type":34},"2025-05-13",{"date":445,"type":21},"2025-05-15",{"date":447,"type":21},"2029-11",{"name":449,"class":41},"University of Sao Paulo",{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":4},"100585322","patients-seeking-a-visual-impairment-certificate-100585322","NCT06900855","Patients Seeking a Visual Impairment Certificate","Prevalence, Causes and Demographic Profile of Patients Seeking a Visual Impairment Certificate","Inclusion Criteria:\n\n* Patients requesting visual impairment certificate at Assiut ophthalmology hospital having all investigations Visual field, OCT macula, VEP, ERG, US, Fundus photography Werepatients who fulfilled WHO's definition of blindness. The blind patients according to WHO's,were defined as patients having best corrected distance visual acuity (BCVA) of 3\u002F60 or less in the better eye or a visual field restricted to 10 or less in the widest diameter of vision.\n\nExclusion Criteria:\n\n* Patients unwilling to participate in the study Incomplete or missing investigations",{"count":458,"type":21},383,"This study investigates the prevalence, causes, and demographic characteristics of patients seeking visual impairment certificates at Assiut Ophthalmology Hospital. Using a prospective cross-sectional design, it aims to identify the magnitude and nature of visual impairment in this population by analyzing clinical data, performing comprehensive eye examinations, and utilizing advanced diagnostic tools.",[461,462,25],"Demographic Profiles","Impairment Certificates",[394,464,465],"demographic profiles","visual impairment certificates","2025-03-22",{"date":468,"type":34},"2025-03-28",{"date":470,"type":21},"2025-05-01",{"date":472,"type":21},"2026-08-30",{"name":474,"class":41},"Assiut University",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":16,"minAge":483,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":53,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":200},"100493300","effectiveness-of-av-stimulation-in-immersive-vr-to-improve-visual-perception-and-driving-performance-100493300","NCT05703360","Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance","Effectiveness of Audiovisual Stimulation in Immersive Virtual Reality to Improve Visual Perception and Driving Performance: a Pilot Study","Re:DriVR","Inclusion Criteria:\n\n* Male and female \\> 25 years old.\n* Visual field defects due to TBI or stroke\n* BCVA ≥ 20\u002F50.\n* Previously held a valid driving license and were active drivers.\n* Ability to follow the visual and auditory stimuli and training instructions.\n* Online auditory test positive (-5dBHL to 60dBHL range) at 125 Hz (for research purposes only)\n* Home Wi-Fi access.\n\nExclusion Criteria:\n\n* Both eyes with media opacity that impairs visual field testing.\n* Inability to perform during testing and training.\n* Cognitive\u002Fmotor condition incompatible with driving simulator and\u002For VR.\n* Recreational or medicinal consumption of psychoactive drugs.\n* 3 consecutive VRISE scores \\\u003C 25 at inclusion.\n* History of vertigo or dizziness.\n* Visual neglect.\n* Prior\u002Fcurrent vision rehabilitation interventions.\n* Photosensitive epilepsy.","25 Years",{"count":485,"type":21},30,[88],"The goal of this clinical trial is to evaluate the effectiveness of an immersive virtual-reality (IVR) based stimulation program, in improving visual perception for people who have lost their driver's license due to perceptual or cognitive impairments.\n\nThe main questions it aims to answer are:\n\n1. Can the 6-week IVR stimulation program help improve driving performance?\n2. Will participants experience improvement in visual detection and perception after training?\n\nStudy Design Summary:\n\n* Participants will be randomized into a waitlist group or intervention-first group\n* The VR-based intervention will consist of training every 2 days for six weeks\n* Waitlist group will wait 6 weeks before starting intervention at study midpoint (week 7)\n* Intervention-first group will begin with intervention (week 1-6) and then stop intervention at study midpoint\n* Participants will complete tests related to driving performance, visual attention, and visual fields at the start of study, midpoint, and end of study\n\nResearchers will analyze data for changes from baseline in outcome measures.",[141,25,489,490,491,492,493,186,494],"Low Vision","Virtual Reality","Visual Spatial Processing","Visual Field Defect","Visual Processing Speed","Driving Impaired","2024-12-16",{"date":497,"type":34},"2024-12-19",{"date":499,"type":21},"2025-02-01",{"date":501,"type":21},"2025-12-01",{"name":503,"class":41},"University Health Network, Toronto",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":83,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":53,"phases":514,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":531,"locationsCount":106},"100528465","filter-lenses-for-the-prevention-of-migraine-attacks-100528465","NCT06161129","Filter Lenses for the Prevention of Migraine Attacks","Filter Lenses for the Prevention of Migraine Attacks - Effects of Blue Cut and FL-41 Filter Lenses","COMFORT","Inclusion criteria:\n\n* Adult individuals below the age of 66.\n* Diagnosed with migraine by a neurologist.\n* Able to communicate in Danish\n* Able to voluntarily come to the clinic during an untreated migraine attack.\n* Must have had migraine attacks for more than 1 year.\n\nExclusion criteria:\n\n* Fewer than four migraine attacks per month.\n* Chronic neck pain\n* Chronic headache\n* Chronic use of opioids\n* Presence of a pathological eye condition (in the study, an eye condition is defined as a permanent eye condition that affects the front and back of the eye, such as glaucoma, age-related macular degeneration)\n* Other acquired and congenital retinal diseases must not be present.\n* If there is more than 1 line of deviation on the Snellen chart from habitual correction to best correction, the participant must have a new pair of glasses made at their own expense.",{"count":513,"type":21},200,[88],"The purpose is to investigate whether the Blue Cut for Night filter is better at reducing migraine compared to the FL-41 filter or a filter blocking light below 500 nm. A control group will use clear lenses without filter. This is a controlled, randomized and double-blind trial.",[517,518,519,25],"Migraine","Glasses","Headache",[517,521,522,523,524],"filter glasses","pain","headache","treatment","2024-12-04",{"date":527,"type":34},"2024-12-09",{"date":216,"type":21},{"date":530,"type":21},"2029-02-01",{"name":532,"class":41},"Rune Skovgaard Rasmussen",{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":540,"targetDuration":4,"studyType":53,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":106},"100563132","evaluation-on-visual-outcome-of-tms-100563132","NCT06612190","Evaluation on Visual Outcome of TMS","Evaluation on Visual Outcome of Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* Post cataract surgery or clear lens\n* Best-corrected visual acuity less than 0.1logMAR\n\nExclusion Criteria:\n\n* Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment;\n* Diagnosed with ocular diseases that affect observation of visual function;\n* History of epileptic seizures;\n* Long term use of psychotropic drugs；\n* Metal implants in the body.",{"count":86,"type":21},[88],"The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients with visual impairment. The main question it aims to answer is:\n\n• Does TMS improve the visual outcome in patients who suffer from visual impairment? Researchers will compare TMS to the control group who will not receive effective TMS treatment) to see if TMS works to improve the visual outcomes of the patients.\n\nParticipants will\n\n* Undergo TMS treatment or no effective TMS for consecutive 5 days.\n* Visit the clinic once every 2 weeks for checkups and tests.",[25],"2024-09-21",{"date":546,"type":34},"2024-09-25",{"date":548,"type":21},"2024-10",{"date":550,"type":21},"2027-10",{"name":552,"class":41},"Evidence Based Cataract Study Group",{"id":554,"slug":555,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":83,"sex":16,"minAge":560,"maxAge":561,"enrollmentInfo":562,"targetDuration":4,"studyType":53,"phases":564,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":575,"locationsCount":4},"100557583","development-and-validation-of-an-automated-self-administered-visual-acuity-system-100557583","NCT06540001","Development and Validation of an Automated Self-administered Visual Acuity System","AutoVA","Inclusion Criteria:\n\n1. Patients age \\>21 and able to give consent\n2. Patients who have at least counting finger vision\n3. Patients who is able to speak in an audible and clear voice\n4. Patients who is able to use a digital device independently (e.g. handphone)\n\nExclusion Criteria:\n\n1. Patients on wheelchair\u002F walking aids\n2. Patients with hearing difficulties\n3. Patients with speech difficulties\n4. Patients who have cognitive impairment\n5. Patients who are hemiplegic\u002F motor dysfunction\n6. Patients who have vision worse than counting fingers\n7. Patients who are pregnant","21 Years","100 Years",{"count":563,"type":21},100,[88],"Visual acuity tests, commonly conducted in clinics and used for health screenings, are becoming more in demand due to an aging population. Current online self-eye check apps are limited as they don\\'t accurately reflect true distance vision assessed in clinical settings. These tests, performed by trained personnel, are time-consuming and can cause delays in clinics. This project aims to develop an automated Visual Acuity (VA) station using AI technologies like speech-to-text and computer vision, hypothesizing that it can match the accuracy of manual assessments by clinic staff, thus potentially reducing waiting times and improving efficiency.",[25],[568],"Visual acuity","2024-08-03",{"date":571,"type":34},"2024-08-06",{"date":573,"type":21},"2024-08-01",{"date":300,"type":21},{"name":576,"class":41},"Tan Tock Seng Hospital",{"id":578,"slug":579,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":586,"conditions":587,"keywords":596,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":106},"100554564","visual-involvement-in-giant-cell-arteritis-100554564","NCT06500728","Visual Involvement in Giant Cell Arteritis","Visu-GCA","Inclusion Criteria:\n\n* For GCA group:\n\n  * Patients older than 18 years with clinically suspected or confirmed gigantocellular arteritis.\n  * Newly found visual involvement with suspected or confirmed correlation with vasculitis.\n  * Ability to express valid consent to study enrolment.\n* For control group:\n\n  * Patients older than 18 years with the ability to express valid consent to study enrolment.\n  * Newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.\n\nExclusion Criteria:\n\n* Pre-existing ophthalmological pathologies that may modify best visual acuity and\u002For alter ophthalmological semeiotics.\n* Concomitant active viral, bacterial, fungal and parasitic infections, including active or latent tuberculosis treated for less than 4 weeks and HIV, hepatitis C virus (HCV)\n\n  \u002Fhepatitis B virus (HBV) infections, involving the eyes and orbital cavities.\n* Concomitant systemic inflammations not attributable to GCA (inflammatory diseases in treatment-free remission are not excluded).\n* Any other condition judged by the investigators to be a contraindication of eligibility",{"count":585,"type":21},762,"This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries.\n\nThe primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.",[588,25,589,590,591,592,593,594,595],"Giant Cell Arteritis","Central Retinal Artery Occlusion","Anterior Ischemic Optic Neuropathy","Paracentral Acute Middle Maculopathy","Posterior Ischemic Optic Neuropathy","Retinal Ischemia","Blindness","Visual Disorder",[588,597,598,599,600,601,602],"Visual impairment","Optical Coherence Tomography (OCT)","High resolution Optical Coherence Tomography (HR-OCT)","Angio-Optical Coherence Tomography (OCT-A)","Fluorescein angiography","Indocyanine green angiography","2024-07-08",{"date":605,"type":34},"2024-07-15",{"date":607,"type":34},"2024-06-27",{"date":609,"type":21},"2030-06",{"name":611,"class":41},"ASST Fatebenefratelli Sacco",{"id":613,"slug":614,"hasResults":11,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":83,"sex":619,"minAge":620,"maxAge":621,"enrollmentInfo":622,"targetDuration":4,"studyType":53,"phases":624,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":106},"100553740","menstrual-health-education-for-visually-impaired-adolescent-100553740","NCT06490016","Menstrual Health Education for Visually Impaired Adolescent","Effect of Web Based Menstrual Health Education on Menstrual Attitude, Menstrual Symptoms and Anxiety Among Visually Impaired Adolescent","Inclusion Criteria:\n\n* For face-to-face education:\n\n  * Be between the ages of 11-19\n  * Ability to read and write\n  * Menstruation\n  * Having at least 60% vision loss (those with congenital or acquired vision loss)\n\nFor web-based training:\n\n* Be between the ages of 11-19\n* Ability to read and write\n* Menstruation\n* Having at least 60% vision loss (those with congenital or acquired vision loss)\n* Having a computer or mobile phone compatible with a screen reader program and internet access.\n\nExclusion Criteria:\n\n• Not attending face-to-face or web-based training for at least 1 week.","FEMALE","11 Years","19 Years",{"count":623,"type":21},35,[88],"This study was planned as a two-group randomized controlled interventional study to determine the effect of face-to-face and web-based menstrual health education given to visually impaired adolescent girls on menstrual attitude, menstrual symptoms and anxiety.",[25,627],"Menstrual Problem",[629,630,631,632,633],"anxiety","health education","nurse","menstruation","visually impaired adolescent","2024-06-28",{"date":603,"type":34},{"date":637,"type":21},"2024-10-20",{"date":639,"type":21},"2026-02-15",{"name":641,"class":41},"Cukurova University",{"id":643,"slug":644,"hasResults":11,"nctId":645,"briefTitle":646,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":11,"sex":16,"minAge":648,"maxAge":649,"enrollmentInfo":650,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":106},"100505723","early-visual-functions-in-patients-at-risk-of-developing-cerebral-visual-impairment-a-pilot-study-100505723","NCT05865093","Early Visual Functions in Patients at Risk of Developing Cerebral Visual Impairment. A Pilot Study","Inclusion Criteria:\n\n* Age between 34 weeks of post-menstrual age and 36 months of life in children born before 37 weeks gestational age\n* Genetic syndroms\n* Hypoxic Hischemic Encephalopathy\n* Brain malformation\n* Metabolic diseases\n* Ocular pathologies\n\nExclusion Criteria:\n\n* Patients at low risk of developing neurological outcomes\n* Refusal of informed consent","2 Days","36 Months",{"count":651,"type":21},700,"The aim of the study is to assess visual function from neonatal age to 36 months of age in infants at risk of visual impairment due to brain lesion or ocular pathology",[25],"2023-05-17",{"date":656,"type":34},"2023-05-18",{"date":658,"type":34},"2022-07-01",{"date":660,"type":21},"2027-06-30",{"name":662,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":664,"slug":665,"hasResults":11,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":671,"targetDuration":380,"studyType":22,"phases":4,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":106},"100497051","quality-of-life-in-italian-visually-impaired-patients-100497051","NCT05752214","Quality of Life in Italian Visually Impaired Patients","Observational Study on Quality of Life in Visually Impaired Patients Through the Questionnaire VA LV VFQ in Italy","SOPIITA","Inclusion Criteria:\n\n* Subjects aged 18 years or older, suffering from any visual pathology, who are admitted to specialised visual rehabilitation centres for visual rehabilitation.\n* Ability to understand and sign the informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Less than 18 years of age.\n* Cognitive impairment that, in the opinion of the investigator, limits understanding of the informed consent or the questionnaire.",{"count":672,"type":21},500,"Clinical register of visual rehabilitation activity and observational study on the validation of the VA LV VFQ questionnaire in the Italian context",[25],"2023-02-21",{"date":677,"type":34},"2023-03-02",{"date":679,"type":34},"2021-05-20",{"date":681,"type":21},"2030-12-31",{"name":683,"class":41},"Amore Filippo"]